Drug news
FDA review of Yaz/Yasmin (Bayer) risk benefit
FDA advisers agreed that the benefits of Bayer Healthcare's drospirenone-containing oral contraceptives, such as Yaz and Yasmin, in preventing pregnancy outweigh the drugs' risks of potentially fatal blood clots. But the Advisory Committees,voted 21-5 that the labelling for the drugs fails to adequately reflect the risk-benefit profile for the products and should contain more graphic language.